The Science Behind

Developing drugs for neurodegenerative disease and central nervous system disorders presents significant challenges including: > Difficulties in assessing Target Engagement. > Heterogeneity and insensitivity in clinical scales. > Translation from pre-clinical studies. > Difficulties in understanding human pathophysiology. > Increasing placebo effects. The Science Behind can help you address these challenges by leveraging our network of neuroscience, neurology, and psychology experts and state-of-the-art neuroscience technology to objectively measure pharmacodynamic endpoints and enable earlier decision making. The Science Behind Limited provides specialist neuroscience technologies and capabilities to Sponsors and clinical contract research organisations (CROs) in phase 1 and first-in-human clinical trials for neurodegenerative and central nervous system disorders. Working with you, our team will identify and select the appropriate tests and measures based on your drug candidate mechanism of action, data from preclinical studies and/or other academic and scientific literature, to build you a tailored solution that gives you meaningful, objective endpoints while seamlessly integrating with other clinical trial measurements. Our aim is to become the preferred partner for those requiring specialist neuroscience expertise and technology for early-phase clinical trials.